Theravance Reports Positive Phase 1 Data on TD-1473, a JAK Inhibitor for IBD

Theravance Reports Positive Phase 1 Data on TD-1473, a JAK Inhibitor for IBD
Theravance Biopharma, Inc., recently reported positive data from its Phase 1 clinical trial assessing TD-1473, a new and oral pan-Janus kinase (JAK) inhibitor designed to enter the gastrointestinal tract and target inflammation without significant systemic exposure. Proinflammatory cytokines play an important role in inflammatory bowel disease (IBD), many of which signal via the JAK/signal transducer and activator of transcription (STAT) pathway. The study was a placebo-controlled, randomized, single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1 trial (NCT02657122) assessing TD-1473 in healthy subjects. Its primary objective was to evaluate the safety
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *